Alzheimer Disease

Naahaad Mukadam, PhD: Addressing the Dementia Public Health Crisis

August 10, 2020


A team of researchers have added 3 new modifiable risk factors to a list of 9 known factors that increase the risk of developing dementia.

Naahaad Mukadam, PhD: The Future of Dementia Care

August 10, 2020


An expert in Alzheimer disease describes some of the struggles dementia patients might be going through during the COVID-19 pandemic.

FDA Sets PDUFA Date on Aducanumab for Alzheimer Disease

August 07, 2020


Investigators found a 22% reduction in clinical decline at the 78-week cutoff in the intent to treat population in EMERGE who received high-dose aducanumab, with a similar reduction seen in the opportunity to complete population.

Flu and Pneumonia Vaccines Could Help Reduce Alzheimer Disease Dementia Risk

July 31, 2020


Three studies presented during the AAIC 2020 annual meeting show how frequent influenza vaccination help promote a gene-dependent reduction of Alzheimer disease by up to 40%.

Annual Alzheimer Disease Pipeline Shows Rapid Progress in Clinical Research

July 24, 2020


As of February, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.

Biogen Submits BLA for Investigational Alzheimer Disease Agent

July 08, 2020


Those who received the agent in EMERGE reported a significant slowing of decline on measures of cognition and function such as memory, orientation, and language, as well as for activities of daily living.

Healthy Lifestyle Aids in Alzheimer Disease Risk Reduction

June 27, 2020


Those with ≥150 min per week in moderated or vigorous activities were low risk while those with less than 150 or sedentary activity were higher risk.

FDA Approves Tau Imaging Agent for Alzheimer Disease

May 29, 2020


The tau tracer can support a pathological diagnosis of Alzheimer disease by identifying the underlying presence of NFTs at the B3 level.

Investigators Tout New Alzheimer Disease Blood Immunoassay Test

May 28, 2020


The new technology has applications for diagnosis and recruitment for disease-modifying trials.

Preliminary Data Positive for Investigational Alzheimer Disease Agent

May 14, 2020


Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.